As of July 17, 40 companies have expressed interest to manufacture it and the applications are being processed, said R Sankara Narayanan, Additional Solicitor General representing DRDO
The petitioner said giving the licence to several medical companies may bring the price down. He sought the court to direct the authorities to provide the licence to multiple pharmaceutical firms.
The anti-COVID drug has been developed by the Defence Research and Development Organisation.
The new drug 2-deoxy-D-glucose (2-DG) is said to help Covid patients with moderate and severe conditions by reducing their oxygen dependence.
Registry data suggests phase-3 clinical trials for 2-DG at over 12 locations may continue till August
The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.
At a press conference, NITI Aayog member (health) Dr V K Paul said Drugs Controller General of India (DCGI) has granted permission for emergency use of the drug after looking at the data.
The Drugs Controller General of India (DGCI) has approved the oral drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients, the defence ministry said.
Speaking to Express, Mishra said the anti Covid-19 therapeutic application of the drug would be a major step in fighting the virus.